Revance Therapeutics reported $711.59M in Assets for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Assets Change
Aerie Pharmaceuticals AERI:US USD 375.59M 9.75M
ALKERMES ALKS:US USD 1.94B 15.52M
Bristol Myers Squibb BMY:US USD 98.2B 2.16B
Cara Therapeutics CARA:US USD 213.51M 13.06M
Coherus Biosciences CHRS:US USD 550.91M 4.9M
Eli Lilly And LLY:US USD 47.46B 397.9M
Endo International Ordinary Shares ENDP:US USD 6.01B 355.8M
Horizon Pharma HZNP:US USD 9.03B 174.39M
JAZZ PHA JAZZ:US USD 10.38B 815.47M
Neurocrine Biosciences NBIX:US USD 2.14B 137.7M
Pacira Pharmaceuticals PCRX:US USD 1.73B 377K
Procter & Gamble PG:US USD 116.28B 926M
Revance Therapeutics RVNC:US USD 711.59M 149.71M
Supernus Pharmaceuticals SUPN:US USD 1.69B 1.84M
Teva Pharmaceutical Industries TEVA:US USD 44.25B 1.68B